Insulin Market: Information By Product Type (Short Acting Human Insulin, Intermediate Acting Human Insulin) Delivery System, Application and Regional Outlook - Forecast Till 2026

Apr 10, 2019   Global Statistics Representing Insulin Market Scenario Increasing prevalence of type-2 diabetes is driving the growth of the market. According to American Diabetes Association, in 2014, the economic cost of diabetes globally was estimated to be USD 612 billion. In 2012, in the United States, the cost of diabetes was USD 245 billion. According to the International Diabetes Federation (IDF), in 2015, approximately 415 million people were suffering from diabetes globally, with 90% of the cases of...
Request Free Sample Report

Table Of Content

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Insulin Market

3.3       Key Market Trends

3.3.1    Drivers

3.3.2    Restraints

3.3.3    Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1    Bargaining Power of Suppliers

3.4.2    Bargaining Power of Buyers

3.4.3    Threat of Substitution

3.4.4    Threat of New Entrants

3.4.5    Competitive Rivalry

3.5       Market Share Analysis

4          By Product Type

4.1       Introduction

4.1.1    Market Size & Forecast (Value)

4.2       Short Acting Human Insulin

4.3       Intermediate Acting Human Insulin

4.4       Long Acting Human Insulin

4.5       Fast Acting Human Insulin

4.6       Premixed Human Insulin

5        By Delivery System

5.1       Introduction 

5.1.1    Market Size & Forecast (Value)

5.2       Syringes

5.3       Pens

5.4       Pens needles

5.5       Pumps

6.         By Application  

6.1       Introduction

6.1.1    Market Size & Forecast (Value)

6.2       Type II Diabetes,

6.3       Type I Diabetes,

6.4       Gestational Diabetes

6.5       Prediabetes

7          Regional

7.1       Introduction

7.1.1    Market Size & Forecast (Value)

7.2       America

7.2.1    North America

7.2.1.1 U.S.

7.2.1.1.1          By Product Type

7.2.1.1.2          By Delivery System

7.2.1.2 Canada

7.2.1.2.1          By Product Type

7.2.1.2.2          By Delivery System

7.2.1.3 Mexico

7.2.1.3.1          By Product Type

7.2.1.3.2          By Delivery System

7.2.2    Latin America

7.2.2.1 By Product Type

7.2.2.2 By Delivery System

7.3       Europe

7.3.1    Market Size & Forecast (Value)

7.3.2    Germany

7.3.2.1 By Product Type

7.3.2.2 By Delivery System

7.3.3    France

7.3.3.1 By Product Type

7.3.3.2 By Delivery System

7.3.4    U.K.

7.3.4.1 By Product Type

7.3.4.2 By Delivery System

7.3.5    Italy

7.3.5.1 By Product Type

7.3.5.2 By Delivery System

7.3.6    Spain

7.3.6.1 By Product Type

7.3.6.2 By Delivery System

7.3.7    Rest of Europe

7.3.7.1 By Product Type

7.3.7.2 By Delivery System

7.4       Asia Pacific

7.4.1    Market Size & Forecast (Value)

7.4.2    Japan

7.4.2.1 By Product Type

7.4.2.2 By Delivery System

7.4.3    China

7.4.3.1 By Delivery System

7.4.3.2 By Delivery System

7.4.4    Australia

7.4.4.1 By Product Type

7.4.4.2 By Delivery System

7.4.5    India

7.4.5.1 By Product Type

7.4.5.2 By Delivery System

7.4.6    South Korea

7.4.6.1 By Product Type

7.4.6.2 By Delivery System

7.4.7    Rest of Asia-Pacific

7.4.7.1 By Product Type

7.4.7.2 By Delivery System

7.5       Middle East & Africa

7.5.1    Market Size & Forecast (Value)

7.5.2    Saudi Arabia

7.5.2.1 By Product Type

7.5.2.2 By Delivery System  

7.5.3    South Africa

7.5.3.1 By Product Type

7.5.3.2 By Delivery System  

7.5.4    Kuwait

7.5.4.1 By Product Type

7.5.4.2 By Delivery System  

7.5.5    Rest of Middle East & Africa

7.5.5.1 By Product Type

7.5.5.2 By Delivery System  

8.         Company Profile

8.1       Life scan Inc.

8.1.1    Company Overview

8.1.2    Financial Performance

8.1.3    Recent Developments

8.1.4    Product Portfolio

8.2       Becton, Dickinson and Co.

8.2.1    Company Overview

8.2.2    Financial Performance

8.2.3    Recent Developments

8.2.4    Product Portfolio

8.3       Terumo Corporation

8.3.1    Company Overview

8.3.2    Financial Performance

8.3.3    Recent Developments

8.3.4    Product Portfolio

8.4       Acon Laboratories Inc.

8.4.1    Company Overview

8.4.2    Financial Performance

8.4.3    Recent Developments

8.4.4    Product Portfolio

8.5       Roche Diagnostics Ltd.

8.5.1    Company Overview

8.5.2    Financial Performance

8.5.3    Recent Developments

8.5.4    Product Portfolio

8.6       Johnson & Johnson

8.6.1    Company Overview

8.6.2    Financial Performance

8.6.3    Recent Developments

8.6.4    Product Portfolio

8.7       ARKRAY Inc.

8.7.1    Company Overview

8.7.2    Financial Performance

8.7.3    Recent Developments

8.7.4    Product Portfolio

8.8       Novo Nordisk A/S

8.8.1    Company Overview

8.8.2    Financial Performance

8.8.3    Recent Developments

8.8.4    Product Portfolio

8.9       Medtronic

8.9.1    Company Overview

8.9.2    Financial Performance

8.9.3    Recent Developments

8.9.4    Product Portfolio

8.10     Abbott Laboratories

8.10.1  Company Overview

8.10.2  Financial Performance

8.10.3  Recent Developments

8.10.4  Product Portfolio

8.11     Bayer AG

8.11.1  Company Overview

8.11.2  Financial Performance

8.11.3  Recent Developments

8.11.4  Product Portfolio

8.12     Ypsomed AG

8.12.1  Company Overview

8.12.2  Financial Performance

8.12.3  Recent Developments

8.12.4  Product Portfolio

8.13     Sanofi

8.13.1  Company Overview

8.13.2  Financial Performance

8.13.3  Recent Developments

8.13.4  Product Portfolio